CytoMed Therapeutics Limited Net Income
| GDTC Stock | 1.04 0.03 2.80% |
As of the 12th of February 2026, CytoMed Therapeutics shows the Risk Adjusted Performance of (0.09), mean deviation of 4.16, and Standard Deviation of 6.52. CytoMed Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
CytoMed Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 60.3256 | Revenue | Earnings Share (0.25) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -2.8 M | -3 M | |
| Net Loss | -1.7 M | -1.7 M | |
| Net Loss | -2.3 M | -2.4 M | |
| Net Loss | (0.19) | (0.20) | |
| Net Income Per E B T | 1.15 | 1.12 |
CytoMed | Net Income | Build AI portfolio with CytoMed Stock |
Analyzing CytoMed Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing CytoMed Therapeutics's current valuation and future prospects.
Latest CytoMed Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of CytoMed Therapeutics Limited over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in CytoMed Therapeutics financial statement analysis. It represents the amount of money remaining after all of CytoMed Therapeutics Limited operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is CytoMed Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CytoMed Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (1.84 M) | 10 Years Trend |
|
Net Income |
| Timeline |
CytoMed Net Income Regression Statistics
| Arithmetic Mean | (1,181,612) | |
| Coefficient Of Variation | (64.60) | |
| Mean Deviation | 645,883 | |
| Median | (632,611) | |
| Standard Deviation | 763,306 | |
| Sample Variance | 582.6B | |
| Range | 2.5M | |
| R-Value | (0.77) | |
| Mean Square Error | 252.2B | |
| R-Squared | 0.59 | |
| Significance | 0.0003 | |
| Slope | (116,511) | |
| Total Sum of Squares | 9.3T |
CytoMed Net Income History
Other Fundumenentals of CytoMed Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
CytoMed Therapeutics Net Income component correlations
CytoMed Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for CytoMed Therapeutics is extremely important. It helps to project a fair market value of CytoMed Stock properly, considering its historical fundamentals such as Net Income. Since CytoMed Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CytoMed Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CytoMed Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could CytoMed diversify its offerings? Factors like these will boost the valuation of CytoMed Therapeutics. Market participants price CytoMed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CytoMed Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.25) | Revenue Per Share | Quarterly Revenue Growth 1.01 | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, CytoMed Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
CytoMed Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to CytoMed Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of CytoMed Therapeutics.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in CytoMed Therapeutics on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding CytoMed Therapeutics Limited or generate 0.0% return on investment in CytoMed Therapeutics over 90 days. CytoMed Therapeutics is related to or competes with Enlivex Therapeutics, MetaVia, NuCana PLC, Neurosense Therapeutics, Lisata Therapeutics, Collplant Biotechnologies, and Neuraxis. CytoMed Therapeutics is entity of United States More
CytoMed Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure CytoMed Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess CytoMed Therapeutics Limited upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 34.75 | |||
| Value At Risk | (10.38) | |||
| Potential Upside | 8.33 |
CytoMed Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for CytoMed Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as CytoMed Therapeutics' standard deviation. In reality, there are many statistical measures that can use CytoMed Therapeutics historical prices to predict the future CytoMed Therapeutics' volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.81) | |||
| Total Risk Alpha | (1.58) | |||
| Treynor Ratio | 10.82 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CytoMed Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
CytoMed Therapeutics February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | 10.83 | |||
| Mean Deviation | 4.16 | |||
| Coefficient Of Variation | (810.62) | |||
| Standard Deviation | 6.52 | |||
| Variance | 42.57 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.81) | |||
| Total Risk Alpha | (1.58) | |||
| Treynor Ratio | 10.82 | |||
| Maximum Drawdown | 34.75 | |||
| Value At Risk | (10.38) | |||
| Potential Upside | 8.33 | |||
| Skewness | 0.444 | |||
| Kurtosis | 5.98 |
CytoMed Therapeutics Backtested Returns
CytoMed Therapeutics secures Sharpe Ratio (or Efficiency) of -0.12, which signifies that the company had a -0.12 % return per unit of risk over the last 3 months. CytoMed Therapeutics Limited exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm CytoMed Therapeutics' Mean Deviation of 4.16, standard deviation of 6.52, and Risk Adjusted Performance of (0.09) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.0753, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning CytoMed Therapeutics are expected to decrease at a much lower rate. During the bear market, CytoMed Therapeutics is likely to outperform the market. At this point, CytoMed Therapeutics has a negative expected return of -0.83%. Please make sure to confirm CytoMed Therapeutics' day median price, period momentum indicator, as well as the relationship between the accumulation distribution and potential upside , to decide if CytoMed Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.73 |
Good predictability
CytoMed Therapeutics Limited has good predictability. Overlapping area represents the amount of predictability between CytoMed Therapeutics time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of CytoMed Therapeutics price movement. The serial correlation of 0.73 indicates that around 73.0% of current CytoMed Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.73 | |
| Spearman Rank Test | 0.48 | |
| Residual Average | 0.0 | |
| Price Variance | 0.05 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
CytoMed Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, CytoMed Therapeutics Limited reported net income of (1.84 Million). This is 100.54% lower than that of the Biotechnology sector and 102.63% lower than that of the Health Care industry. The net income for all United States stocks is 100.32% higher than that of the company.
CytoMed Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CytoMed Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CytoMed Therapeutics could also be used in its relative valuation, which is a method of valuing CytoMed Therapeutics by comparing valuation metrics of similar companies.CytoMed Therapeutics is currently under evaluation in net income category among its peers.
CytoMed Fundamentals
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (4.52) % | ||||
| Current Valuation | 10.69 M | ||||
| Shares Outstanding | 11.73 M | ||||
| Shares Owned By Insiders | 67.35 % | ||||
| Shares Owned By Institutions | 0.43 % | ||||
| Number Of Shares Shorted | 14.27 K | ||||
| Price To Book | 2.23 X | ||||
| Price To Sales | 17.20 X | ||||
| Revenue | 52.01 K | ||||
| Gross Profit | 675.25 K | ||||
| EBITDA | (1.79 M) | ||||
| Net Income | (1.84 M) | ||||
| Total Debt | 339.2 K | ||||
| Book Value Per Share | 0.62 X | ||||
| Cash Flow From Operations | (1.69 M) | ||||
| Short Ratio | 0.10 X | ||||
| Earnings Per Share | (0.25) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 43 | ||||
| Beta | -0.35 | ||||
| Market Capitalization | 22.53 M | ||||
| Total Asset | 7.37 M | ||||
| Retained Earnings | (10.87 M) | ||||
| Working Capital | 5.39 M | ||||
| Net Asset | 7.37 M |
About CytoMed Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CytoMed Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CytoMed Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CytoMed Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CytoMed Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CytoMed Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytomed Therapeutics Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytomed Therapeutics Limited Stock:Check out You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Will Biotechnology sector continue expanding? Could CytoMed diversify its offerings? Factors like these will boost the valuation of CytoMed Therapeutics. Market participants price CytoMed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CytoMed Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.25) | Revenue Per Share | Quarterly Revenue Growth 1.01 | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, CytoMed Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.